Core Insights - BioAge Labs has initiated a Phase 1 clinical trial for BGE-102, an oral CNS-penetrant NLRP3 inhibitor, with initial single ascending dose data expected by the end of 2025 [2][3] - The company is advancing its oral and parenteral APJ agonist programs, targeting IND submissions in 2026 [2][4] - BioAge reported collaboration revenue of $2.1 million for Q3 2025, attributed to its partnership with Novartis [6][7] - The net loss for Q3 2025 was $20.2 million, an improvement from a net loss of $23.4 million in Q3 2024 [10][16] Clinical Development - The Phase 1 trial for BGE-102 is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants, with top-line data from a proof-of-concept trial expected in the second half of 2026 [3][12] - The APJ agonist program includes a collaboration with JiKang Therapeutics to develop a novel APJ agonist nanobody, which shows at least 10-fold greater potency than apelin [4] Financial Performance - Research and development expenses decreased to $18.5 million in Q3 2025 from $20.0 million in Q3 2024, primarily due to the termination of azelaprag development [8] - General and administrative expenses increased to $6.7 million in Q3 2025 from $4.7 million in Q3 2024, driven by higher legal fees and personnel-related expenses [9] - As of September 30, 2025, BioAge had approximately $295.9 million in cash and marketable securities, sufficient to fund operations through 2029 [11][18]
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates